VYROLOGIX Trademark

Trademark Overview

On Tuesday, October 8, 2019, a trademark application was filed for VYROLOGIX with the United States Patent and Trademark Office. The USPTO has given the VYROLOGIX trademark a serial number of 88646441. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, May 23, 2022. This trademark is owned by CytoDyn Inc.. The VYROLOGIX trademark is filed in the Pharmaceutical Products category with the following description:

Therapeutic preparations, namely, antibodies for use in targeting the CCR5 cell receptor, for treating HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis; therapeutic preparations for the treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis
vyrologix

General Information

Serial Number88646441
Word MarkVYROLOGIX
Filing DateTuesday, October 8, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, May 23, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 25, 2020

Trademark Statements

Goods and ServicesTherapeutic preparations, namely, antibodies for use in targeting the CCR5 cell receptor, for treating HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis; therapeutic preparations for the treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, October 12, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCytoDyn Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressVancouver, WA 98660
Party NameCytoDyn Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressVancouver, WA 98660

Trademark Events

Event DateEvent Description
Monday, May 23, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, May 23, 2022ABANDONMENT - NO USE STATEMENT FILED
Thursday, October 14, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 12, 2021SOU EXTENSION 3 GRANTED
Tuesday, October 12, 2021SOU EXTENSION 3 FILED
Tuesday, October 12, 2021SOU TEAS EXTENSION RECEIVED
Friday, April 23, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, April 21, 2021SOU EXTENSION 2 GRANTED
Wednesday, April 21, 2021SOU EXTENSION 2 FILED
Wednesday, April 21, 2021SOU TEAS EXTENSION RECEIVED
Thursday, October 22, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 20, 2020SOU EXTENSION 1 GRANTED
Tuesday, October 20, 2020SOU EXTENSION 1 FILED
Tuesday, October 20, 2020SOU TEAS EXTENSION RECEIVED
Tuesday, April 21, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 25, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 25, 2020PUBLISHED FOR OPPOSITION
Wednesday, February 5, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, January 17, 2020ASSIGNED TO LIE
Tuesday, January 14, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, January 14, 2020EXAMINER'S AMENDMENT ENTERED
Tuesday, January 14, 2020NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, January 14, 2020EXAMINERS AMENDMENT E-MAILED
Tuesday, January 14, 2020EXAMINERS AMENDMENT -WRITTEN
Monday, January 13, 2020ASSIGNED TO EXAMINER
Saturday, October 12, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, October 11, 2019NEW APPLICATION ENTERED

Related Keywords

vyrologix disease host versus autoimmune diseases steatohepatitis nonalcoholic graft cancer therapeutic